Agilent Taps Cirena To Turn Long RNA Technology Into Genome Editing Growth

May 11, 2026 - 01:37

Agilent Technologies has signed a licensing agreement with Cirena, granting the company access to its long RNA purification technology for use in genome editing. The deal targets the scalable production of high-purity long RNA constructs, which are essential for CRISPR and functional genomics applications. This move allows Agilent to expand its footprint in synthetic RNA tools, moving beyond its traditional focus on diagnostics and measurement systems.

Under the terms of the agreement, Cirena will use Agilent's proprietary technology to develop and manufacture long RNA molecules. These constructs are critical for advanced gene editing workflows, where purity and scalability remain major hurdles. By leveraging Agilent's purification methods, Cirena aims to improve the consistency and yield of RNA used in research and therapeutic development.

For Agilent, the partnership represents a strategic shift into the fast-growing genome editing market. The company has long been known for its analytical instruments and diagnostic solutions, but this licensing deal signals a broader ambition to become a key supplier of raw materials for gene therapy and synthetic biology. Financial terms of the deal were not disclosed.